Celldex Therapeutics, Inc. (CLDX) Earnings History
Net Loss39 years of earnings data (1987–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Celldex Therapeutics, Inc. (CLDX) Earnings Overview
As of June 22, 2026, Celldex Therapeutics, Inc. (CLDX) reported trailing twelve-month net income of -$284M, reflecting -59.2% year-over-year growth. The company earned $-4.26 per diluted share over the past four quarters, with a net profit margin of -17253.3%.
Looking at the long-term picture, CLDX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 1989.
Celldex Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), ARDX (-$58M net income, -15.1% margin), RCUS (-$369M net income, -142.9% margin), CLDX has comparable earnings metrics. Compare CLDX vs IMVT →
CLDX Earnings vs Peers
Earnings metrics vs comparable public companies
CLDX Historical Earnings Data (1987–2025)
39 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$259M | -63.9% | -$287M | $-3.90 | -17253.3% | -19160.0% |
| 2024 | -$158M | -11.6% | -$195M | $-2.45 | -2248.8% | -2778.9% |
| 2023 | -$141M | -25.9% | -$155M | $-2.92 | -2054.8% | -2245.3% |
| 2022 | -$112M | -59.3% | -$115M | $-2.40 | -4765.6% | -4889.0% |
| 2021 | -$71M | -18.0% | -$71M | $-1.64 | -1516.0% | -1531.8% |
| 2020 | -$60M | -17.5% | -$63M | $-2.02 | -805.9% | -854.1% |
| 2019 | -$51M | +66.3% | -$55M | $-3.51 | -1424.0% | -1540.2% |
| 2018 | -$151M | -62.5% | -$156M | $-14.48 | -1585.1% | -1640.1% |
| 2017 | -$93M | +27.6% | -$122M | $-10.86 | -730.1% | -953.7% |
| 2016 | -$129M | -1.0% | -$133M | $-18.99 | -1894.0% | -1958.7% |
| 2015 | -$127M | -7.7% | -$130M | $-19.66 | -2321.1% | -2363.9% |
| 2014 | -$118M | -44.8% | -$122M | $-19.81 | -3292.8% | -3414.1% |
| 2013 | -$82M | -37.9% | -$81M | $-15.33 | -1983.7% | -1981.1% |
| 2012 | -$59M | -32.0% | -$58M | $-15.37 | -527.8% | -518.5% |
| 2011 | -$45M | -1668.6% | -$43M | $-17.01 | -483.5% | -468.4% |
| 2010 | -$3M | +93.1% | -$6M | $-1.19 | -5.4% | -13.8% |
| 2009 | -$37M | +23.1% | -$33M | $-27.64 | -240.6% | -216.4% |
| 2008 | -$48M | -119.5% | -$34M | $-50.12 | -637.1% | -456.0% |
| 2007 | -$22M | -6.2% | -$23M | $-39.80 | -424.0% | -447.9% |
| 2006 | -$20M | -12.6% | -$22M | $-49.41 | -413.2% | -453.6% |
| 2005 | -$18M | -37.1% | -$19M | $-43.93 | -586.0% | -610.8% |
| 2004 | -$13M | -4.2% | -$14M | $-32.57 | -192.5% | -198.0% |
| 2003 | -$13M | +8.4% | -$12M | $-36.48 | -273.5% | -253.3% |
| 2002 | -$14M | +39.2% | -$14M | $-41.17 | -206.3% | -215.2% |
| 2001 | -$23M | -3.5% | -$25M | $-70.63 | -680.0% | -734.1% |
| 2000 | -$22M | -94.3% | -$15M | $-75.43 | -2879.3% | -2023.2% |
| 1999 | -$11M | +78.2% | -$12M | $-46.18 | -762.3% | -805.1% |
| 1998 | -$52M | -295.4% | -$8M | $-281.04 | -2354.5% | -361.3% |
| 1997 | -$13M | -21.3% | -$8M | $-89.06 | -1091.7% | -641.7% |
| 1996 | -$11M | -30.1% | -$12M | $-89.61 | -981.8% | -1072.7% |
| 1995 | -$8M | +28.4% | -$12M | $-85.46 | -207.5% | -295.0% |
| 1994 | -$12M | -48.7% | -$10M | $-122.55 | -165.7% | -135.7% |
| 1993 | -$8M | -116.7% | -$9M | $-82.48 | -86.7% | -104.4% |
| 1992 | -$4M | +21.7% | -$5M | $-48.26 | -54.5% | -71.2% |
| 1991 | -$5M | -35.3% | -$7M | $-57.95 | -51.7% | -73.0% |
| 1990 | -$3M | -240.0% | -$4M | $-18.89 | -33.3% | -43.1% |
| 1989 | -$1M | +9.1% | -$2M | $-23.80 | -9.2% | -17.4% |
| 1988 | -$1M | +8.3% | -$2M | $-26.22 | -23.9% | -43.5% |
| 1987 | -$1M | - | -$2M | $-17.49 | -54.5% | -72.7% |
Download Data
Export CLDX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
39+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLDX — Frequently Asked Questions
Quick answers to the most common questions about buying CLDX stock.
What is CLDX earnings per share (EPS)?
CLDX trailing twelve-month (TTM) diluted EPS is $-4.26, reflecting -59.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1987 to 2025 is available in the table on this page.
What is Celldex Therapeutics, Inc.'s net income?
Celldex Therapeutics, Inc. (CLDX) trailing twelve-month net income is $-284M as of 2025. Earnings declined -59.2% year-over-year.
Is CLDX profitable?
CLDX is not currently profitable on a TTM basis, reporting a net loss of $-284M. Net margin is -17253.3%. Investors should monitor for a return to profitability.
What is CLDX's earnings growth rate?
CLDX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1987 to 2025.
What are CLDX's profit margins?
Celldex Therapeutics, Inc. net profit margin is -17253.3%, operating margin is -19160.0%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -40.6%.
Is CLDX growing earnings?
CLDX earnings are declining — EPS fell -59.2% year-over-year. TTM net income dropped to $-284M. This contrasts with the 5-year CAGR of N/A.
What was CLDX's best earnings year?
Celldex Therapeutics, Inc.'s highest annual net income on record is $-1M, achieved in fiscal year 1989. Earnings history on this page spans 1987 to 2025 and includes all annual and quarterly figures.
What were CLDX's earnings last quarter?
CLDX's most recent reported quarter was Q1 2026. Net income was $-79M with diluted EPS of $-1.18. For a full breakdown of all quarters, see the quarterly earnings table on this page.